China Medical Group (01093.HK): Luncarituzumab injection approved for clinical trials in China.

Zhixin Finance APP News, Shiyao Group (01093.HK) announced that the company's Lenalidomide Injection has been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China. It is the first domestically approved Lenalidomide Injection biosimilar drug in China.